CM
Crystal Mackall
Research areas: Medicine · Oncology · CAR-T cell therapy research · Immunotherapy and Immune Responses · T-cell and B-cell Immunology
0000-0003-0359-9023
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (459)
- Peripheral Blasts at Apheresis as a Risk Factor for Survival following Tisagenlecleucel in Children and Young Adults. Save
- Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function. Save
- HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL. Save
- Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma. Save
- Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma. Save
- CD33-CAR INKT CELLS MITIGATE THE IMPACT OF ANTIGENIC HETEROGENEITY IN ACUTE MYELOID LEUKEMIA THROUGH DIRECT CYTOTOXICITY AND ACTIVATION OF CONVENTIONAL T CELLS Save
- Cell Cycle Sensing Shapes Human T Cell Fate and Exhaustion Programs. Save
- Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis. Save
- Engineering Tumor-Targeted Lentiviral Particles to Deliver CAR Antigens and Lethality Inducing Payloads Save
- B7H3 CAR T cell therapy across immunocompetent ovarian cancer models with evidence of transferable anti-tumor immunity Save
- Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia Save
- Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Save
- Decoding the medulloblastoma surfaceome prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy Save
- IL-18 secreting CAR-T cells uncover divergent immune mechanisms of antigen-heterogeneous solid tumor clearance. Save
- Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity Save
- Surface localized nuclear envelope proteins define a therapeuticvulnerability in MYC-driven Group 3 medulloblastoma Save
- Efficacy of nuclear envelope protein targeting CAR T cell therapy for MYC driven group 3 medulloblastoma Save
- Dynamic, single-cell monitoring of CAR T cell identity and activation with Raman spectroscopy. Save
- Programmable JAK/STAT signaling drives CAR T cells to enhanced functional states Save
- Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis Save